Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study

Lacayo, Eduardo A.; Velayati, Sara; Elsakka, Ahmed; Brody, Lynn A.; Erinjeri, Joseph P.; Ziv, Etay; Boas, F. Edward; Sofocleous, Constantinos T.; Silk, Mikhail; Makker, Vicky; Tew, William P.; Yarmohammadi, Hooman

doi:10.1016/j.jvir.2020.11.011

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumours' heterogeneous microstructure, aggressive behaviour and the vascularity index are the factors that decrease the effectiveness of treatment regimens, especially in locoregional therapies. The results from the other studies have demonstrated survival rates of 7 to 15 months after radioembolisation in patients with different kinds of metastatic liver disease [23,24,25,26]. In our study, patients with ovarian, stomach and pancreas cancer did not show a response after treatment.…”

Section: Discussioncontrasting

confidence: 44%

The value of radioembolisation therapy on metastatic liver tumours – a single centre experience

et al. 2023

View full text Add to dashboard Cite

Objective Local treatments used in metastatic liver tumours efficiently control the disease and survival. Transarterial radioembolisation (TARE) is a safely used locoregional treatment method. We aim to investigate the impact of TARE on different kinds of metastatic liver tumours and the effect of pre-treatment clinical findings. Material and Methods The patients with metastatic liver tumours referred to our department for radioembolisation were retrospectively evaluated. All patients were given a Y-90 glass microsphere after being selected by the appropriate clinical and imaging criteria, lung shunt fraction levels, vascular investigation, and macro aggregated albumin (MAA) scintigraphy performed in the angiography unit. Results Thirty-four (17 women, 17 men) patients were suitable for the treatment. Patients were treated with 115.88±47.84 Gy Y-90 glass Microspheres. The mean survival rate was 14.59±12.59 months after treatment. Higher survival rates were detected in patients who had higher pre-treatment serum albumin levels. The optimum cut-off value of albumin to predict response to treatment was 4 g/dl with 88.89% sensitivity, 62.50% specificity, 72.73% PPV and 83.33% NPV. Furthermore, one unit increase in age increased mortality 1.152 times in our patient group. Conclusion Radioembolisation is a safe and efficient method for controlling metastatic liver disease. Albumin levels significantly affect predicting response; higher albumin levels are related to higher survival rates. Furthermore, older age positively correlated with mortality rates in our patient group.

show abstract

Section: Discussioncontrasting

confidence: 44%